AlloVir   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Houston TX United States (2013)

Organization Overview

First Clinical Trial
2020
NCT04401410
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

AlloVir

Active Ingredients

Drugs in Phase 3 Trials (1)

Posoleucel (5 trials)

Drugs in Phase 2 Trials (1)

alvr106 (1 trial)

Drugs in Phase 1 Trials (1)

partially hla-matched virus specific t cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cystitis (Phase 3)

Virus Diseases (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 3